CLOSED-ACCESS TECHNOLOGY PARTNERSHIP · ADMISSION BY QUALIFICATION ONLY

Technology Partnership.
Defined by Scope.

NDA-protected diligence begins with evidence review. Any rights, transfer or exclusivity terms are defined only in signed agreements and depend on the project scope.

REQUEST Q4 ALLOCATIONBrowse Research Library
DUE-DILIGENCE RECORD — PUBLIC SOURCESDUNS 426683105 · VAT PL9571026227
2009

OPERATING SINCE

Gdynia, Poland

↳ Legal Hub

0

CONSUMER BRANDS

Pure-play B2B model

↳ Legal Hub

LEGAL

DUE-DILIGENCE RECORDS

Current registry and certificate scope

↳ Legal Hub

PROJECT

EVIDENCE ROUTE

Product and market-specific

↳ Signed scope

SIGNED

RIGHTS & CONFIDENTIALITY

Defined in project agreements

↳ Project documentation

EXTERNAL

EVIDENTIARY TESTING

Qualified laboratories where required

↳ Project-specific strategy

PUBLISHED CERTIFICATE RECORDSReview current Legal Hub records

Certificate status and scope are published and maintained in the Legal Hub.

Current public registry and certificate records are available in the Legal Hub. Project documentation is reviewed within the signed diligence scope.

Public evidence is limited to the records linked above; project-specific evidence follows the agreed diligence scope.

ISO 27001:2023 Certified

Information Security — Audited by POLCARGO GROUP Ltd

PURE-PLAY B2B MODEL

Zero consumer brands

FDA FACILITY REGISTRATION

Facility-registration record

OPERATING SINCE 2009

Public due-diligence record

Operating Record and Diligence Evidence

Every partnership is a long-term scientific collaboration — not a transaction.

Zero Consumer Brands

Olympia Biosciences™ operates a pure-play B2B model and owns zero consumer brands.

Operating Record and Diligence Evidence

Current public records and project-specific documentation support diligence; requirements are assessed before scope is agreed.

Technology Fit Assessment

Delivery-system fit, evidence needs and project constraints are evaluated within the agreed diligence scope.

Contract-Defined Rights Path

Rights, transfer conditions and any exclusivity are defined only in signed agreements.

The Access Architecture

Access is structured around scientific alignment — not selected from a menu.

Qualification Dossier Review

Entry-level strategic screening for executive teams validating transfer risk, clinical fit, and IP defensibility.

  • Therapeutic thesis triage summary
  • Targeted dossier shortlisting
  • Pre-NDA strategic fit scoring
  • Executive screening call (admission dependent)
SUBMIT CLINICAL PROTOCOL

Strategic Diligence Track

NDA-protected diligence for teams preparing high-value launch, transfer, or buyout-readiness mandates.

  • Full technical dossier room access
  • Priority scientific diligence sessions
  • Contract-defined rights discussion
  • NDA-protected documentation workshop
  • Named project contact
REQUEST Q4 ALLOCATION

Contract-Defined Technology Transfer Mandate

A scoped pathway for defined technology, contracted project deliverables and industrial onboarding.

  • Contract-defined rights and deliverables
  • Documentation review within signed scope
  • Manufacturing transition planning
  • Co-development subject to scope
  • Named project contact
SUBMIT CLINICAL PROTOCOL

How Partner Access Works — Step by Step

  1. 01

    Protocol Submission

    Submit executive mandate details, transfer objectives, and target therapeutic domain for first-pass qualification.

  2. 02

    NDA & Diligence Gate

    Mutual NDA and intent framing are completed before proprietary documents enter diligence workflows.

  3. 03

    Scientific Diligence Session

    Focused session to review project evidence, risks and scope boundaries.

  4. 04

    Documented Next Step

    Qualified teams receive a documented next-step proposal. Any rights, transfer or exclusivity terms remain subject to signed agreements.

Explore Our Published Research

Browse Research Library10 Tech AdvantagesOlimpia Baranowska

Ready to Access
the Full R&D Dossiers?

Relevant documentation is reviewed under the agreed diligence scope; published records remain available for buyer due diligence.

SUBMIT CLINICAL PROTOCOL

RELATED INTELLIGENCE

Supplement Formulation TechnologyLiposomal, micellar and nano-delivery systems available to partnersEXPLORE ›Physician Brand Supplement CDMOClinical manufacturing pathway for physician-led supplement brandsEXPLORE ›FSMP & Medical Food ManufacturingEU Reg. 2016/128 clinical nutrition production for partner programsEXPLORE ›R&D Intelligence HubFull-depth clinical evidence dossiers available to registered partnersEXPLORE ›Science-First Manifesto — Our Partnership StandardWe partner only with operators who share our evidence-based medicine commitmentEXPLORE ›